ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis.
Yingjin Wang, Hui Yang, Baoyuan Zhang, Yongsu Ma, Kuangen Zhang, Peng Wang, Jiapeng Yang, Zaiqi Wang, Rong Liu, Xiaodong Tian and 2 more
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Hui YangTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Baoyuan ZhangInxMed (Shanghai) Co., Ltd., Shanghai, China.
Kuangen ZhangTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Peng WangTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Jiapeng YangTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Zaiqi WangInxMed (Shanghai) Co., Ltd., Shanghai, China.
Xiaodong TianDepartment of Hepatobiliary Pancreatic Surgery, Peking University First Hospital, Beijing, China.
Ning ZhangTranslational Cancer Research Center, Peking University First Hospital, Beijing, China.
Funding
National High Level Hospital Clinical Research Funding (Interdepartmental Research Project of Peking University First Hospital 2023IR23National High Level Hospital Clinical Research Funding (Interdepartmental Research Project of Peking University First Hospital 2024IR11National High Level Hospital Clinical Research Funding (Scientific Research Fund of Peking University First Hospital 2024XTZ10National High Level Hospital Clinical Research Funding (Scientific Research Seed Fund of Peking University First Hospital 2023SF47National High Level Hospital Clinical Research Funding (Youth Clinical Research Project of Peking University First Hospital 2023YC06National Key Research and Development Program of China 2021YFA0909900National Key Research and Development Program of China 2023YFC2413400National Natural Science Foundation of China 82003187National Natural Science Foundation of China 82171722National Natural Science Foundation of China 82271764National Natural Science Foundation of China 82471772National Natural Science Foundation of China 82573723National Natural Science Foundation of China 82588201Research and Translational Application of Clinical Characteristic Diagnosis and Treatment Techniques in the Capital Z221100007422070Star of Outlook" Scientific Research Project of Peking University First Hospital 2024XW02Young Elite Scientists Sponsorship Program of the Beijing High Innovation Plan 20250797
6 · The paper itselfAbstract
Chemoresistance in pancreatic ductal adenocarcinoma (PDAC) is common and complex, accompanied with chemotherapy process. Gemcitabine-based chemotherapy regimens have shown limited antitumor effects for PDAC, and combination targets are urgently needed to restrict chemoresistance. We attempted to identify the candidate targets with gemcitabine (Gem) through scRNA-seq and bulk-seq analysis based on chemotherapy-treated and Gem-resistant (GR) samples, respectively. The mechanisms were investigated with experimental validation in vitro and in vivo preclinical PDAC models. We found that chemoresistance and evolution after chemotherapy of PDAC were associated with activation of focal adhesion signal. Mechanistically, the focal adhesion kinase (FAK) inhibitor (IN10018) could restrict chemoresistance to Gem of PDAC by targeting SLC7A11-mediated ferroptosis through PI3K-Akt signaling pathway. For tumor microenvironment, IN10018 reduced the abundance of mesenchymal components and enhanced CD8
Indexed as
Amino Acid Transport System y+Carcinoma, Pancreatic DuctalDrug Resistance, NeoplasmFerroptosisFocal AdhesionsPancreatic NeoplasmsAnimalsCell Line, TumorDeoxycytidineFocal Adhesion Protein-Tyrosine KinasesGemcitabineHumansMiceSignal TransductionTumor MicroenvironmentAmino Acid Transport System y+DeoxycytidineFocal Adhesion Protein-Tyrosine KinasesGemcitabineSLC7A11 protein, humanchemoresistanceferroptosisfocal adhesion kinasepancreatic cancerscRNA‐seq
Identifiers
PMID42003743
PMCPMC13334639
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390